These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 16764778)
41. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression. Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951 [TBL] [Abstract][Full Text] [Related]
42. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Soulitzis N; Karyotis I; Delakas D; Spandidos DA Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871 [TBL] [Abstract][Full Text] [Related]
43. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661 [TBL] [Abstract][Full Text] [Related]
44. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606 [TBL] [Abstract][Full Text] [Related]
45. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men. Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534 [TBL] [Abstract][Full Text] [Related]
46. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Okegawa T; Kinjo M; Nutahara K; Higashihara E Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552 [TBL] [Abstract][Full Text] [Related]
47. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Das S; Roth CP; Wasson LM; Vishwanatha JK Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178 [TBL] [Abstract][Full Text] [Related]
48. IGF2 DMR0 methylation, loss of imprinting, and patient prognosis in esophageal squamous cell carcinoma. Murata A; Baba Y; Watanabe M; Shigaki H; Miyake K; Ishimoto T; Iwatsuki M; Iwagami S; Yoshida N; Oki E; Morita M; Nakao M; Baba H Ann Surg Oncol; 2014 Apr; 21(4):1166-74. PubMed ID: 24318096 [TBL] [Abstract][Full Text] [Related]
49. Glutathione S-transferase M1 gene but not insulin-like growth factor-2 gene or epidermal growth factor gene is associated with prostate cancer. Lai MT; Chen RH; Tsai FJ; Wan L; Chen WC Urol Oncol; 2005; 23(4):225-9. PubMed ID: 16018936 [TBL] [Abstract][Full Text] [Related]
50. Thrombin receptor expression is upregulated in prostate cancer. Kaushal V; Kohli M; Dennis RA; Siegel ER; Chiles WW; Mukunyadzi P Prostate; 2006 Feb; 66(3):273-82. PubMed ID: 16245281 [TBL] [Abstract][Full Text] [Related]
51. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia. Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762 [TBL] [Abstract][Full Text] [Related]
52. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617 [TBL] [Abstract][Full Text] [Related]
53. Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis. Narita S; Tsuchiya N; Saito M; Inoue T; Kumazawa T; Yuasa T; Nakamura A; Habuchi T Prostate; 2008 Feb; 68(3):321-35. PubMed ID: 18175332 [TBL] [Abstract][Full Text] [Related]
54. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441 [TBL] [Abstract][Full Text] [Related]
55. Reverse transcriptase-PCR analysis of apoptosis-regulating gene expression in human benign prostatic hyperplasia. Angelucci C; Iacopino F; Lama G; Zelano G; Gianesini G; Sica G; Bono AV Anticancer Res; 2005; 25(6B):3937-41. PubMed ID: 16309180 [TBL] [Abstract][Full Text] [Related]
56. Insulin-like growth factor-I produced by seminal vesicles: relationship to intraepithelial basal cell hyperplasia in the prostate. Garcia FU; Urbanska K; Koltowski L; Reiss K; Sell C Clin Cancer Res; 2007 Jun; 13(11):3140-6. PubMed ID: 17545516 [TBL] [Abstract][Full Text] [Related]
57. Beta1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment. Goel HL; Moro L; King M; Teider N; Centrella M; McCarthy TL; Holgado-Madruga M; Wong AJ; Marra E; Languino LR Cancer Res; 2006 Jan; 66(1):331-42. PubMed ID: 16397247 [TBL] [Abstract][Full Text] [Related]
58. An avaII restriction fragment length polymorphism in the insulin-like growth factor II gene and the occurrence of smooth muscle tumors. Gloudemans T; Pospiech I; Van der Ven LT; Lips CJ; Den Otter W; Sussenbach JS Cancer Res; 1993 Dec; 53(23):5754-8. PubMed ID: 7902208 [TBL] [Abstract][Full Text] [Related]
59. TP53 mutation in prostate needle biopsies--comparison with patients follow-up. Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585 [TBL] [Abstract][Full Text] [Related]